YolTech Therapeutics Partners with Salubris Pharmaceuticals to Develop and Commercialize YOLT-101 in Mainland China
Shots:
- YolTech has signed an exclusive licensing agreement with Salubris to develop & commercialize YOLT-101 across Mainland China
- Salubris secured exclusive rights to develop & commercialize YOLT-101 across Mainland China (except Hong Kong, Macau & Taiwan). YolTech will get $28.76M (RMB 205M) upfront & development milestone as well as $116.47M (~RMB 830M) commercial milestone plus tiered royalties, making it a total deal value of ~$0.1452B (~RMB 1.035B)
- YolTech will continue the non-clinical study of YOLT-101 after excecution, with Salubris handling its clinical development in the licensed territory. In addition, drug showed sustained LDL-C reduction with a single dose in non-human primate models
Ref: PRNewswire | Image: YolTech Therapeutics & Salubris Pharmaceuticals
Related News:- Everest Medicines’ Xerava (eravacycline) Receives NMPA’s Approval for Complicated Intra-Abdominal Infections in Adult Patients
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
